Pulse Biosciences (PLSE) Stock Overview
Operates as a novel bioelectric medicine company. More details
| Snowflake Score | |
|---|---|
| Valuation | 1/6 |
| Future Growth | 0/6 |
| Past Performance | 0/6 |
| Financial Health | 6/6 |
| Dividends | 0/6 |
PLSE Community Fair Values
Create NarrativeSee what others think this stock is worth. Follow their fair value or set your own to get alerts.
Pulse Biosciences, Inc. Competitors
Price History & Performance
| Historical stock prices | |
|---|---|
| Current Share Price | US$15.30 |
| 52 Week High | US$25.00 |
| 52 Week Low | US$9.70 |
| Beta | 1.63 |
| 1 Month Change | -11.56% |
| 3 Month Change | -4.73% |
| 1 Year Change | 42.46% |
| 3 Year Change | 688.66% |
| 5 Year Change | 44.07% |
| Change since IPO | 266.91% |
Recent News & Updates
Here's Why We're Not At All Concerned With Pulse Biosciences' (NASDAQ:PLSE) Cash Burn Situation
Jun 12
We're Not Very Worried About Pulse Biosciences' (NASDAQ:PLSE) Cash Burn Rate
Feb 07Recent updates
Here's Why We're Not At All Concerned With Pulse Biosciences' (NASDAQ:PLSE) Cash Burn Situation
Jun 12We're Not Very Worried About Pulse Biosciences' (NASDAQ:PLSE) Cash Burn Rate
Feb 07Pulse Biosciences Stock: Signs Of Life Following Q1 Update
May 16We're Keeping An Eye On Pulse Biosciences' (NASDAQ:PLSE) Cash Burn Rate
May 10We Think Pulse Biosciences (NASDAQ:PLSE) Can Afford To Drive Business Growth
Dec 25We Think Pulse Biosciences (NASDAQ:PLSE) Can Afford To Drive Business Growth
Sep 04Pulse Biosciences (NASDAQ:PLSE) Has Debt But No Earnings; Should You Worry?
Mar 08Pulse Biosciences appoints Kevin Danahy as CEO; Darrin Uecker to serve as CTO
Sep 20Companies Like Pulse Biosciences (NASDAQ:PLSE) Could Be Quite Risky
Apr 04Is Pulse Biosciences (NASDAQ:PLSE) Using Debt In A Risky Way?
Oct 29Is Pulse Biosciences (NASDAQ:PLSE) In A Good Position To Invest In Growth?
Mar 31Who Has Been Buying Pulse Biosciences, Inc. (NASDAQ:PLSE) Shares?
Feb 24Shareholder Returns
| PLSE | US Medical Equipment | US Market | |
|---|---|---|---|
| 7D | -3.0% | -0.7% | 0.0005% |
| 1Y | 42.5% | 5.5% | 10.0% |
Return vs Industry: PLSE exceeded the US Medical Equipment industry which returned 5.3% over the past year.
Return vs Market: PLSE exceeded the US Market which returned 10.4% over the past year.
Price Volatility
| PLSE volatility | |
|---|---|
| PLSE Average Weekly Movement | 7.9% |
| Medical Equipment Industry Average Movement | 8.6% |
| Market Average Movement | 7.7% |
| 10% most volatile stocks in US Market | 17.4% |
| 10% least volatile stocks in US Market | 4.0% |
Stable Share Price: PLSE has not had significant price volatility in the past 3 months compared to the US market.
Volatility Over Time: PLSE's weekly volatility (8%) has been stable over the past year.
About the Company
| Founded | Employees | CEO | Website |
|---|---|---|---|
| 2014 | 75 | Paul LaViolette | www.pulsebiosciences.com |
Pulse Biosciences, Inc. operates as a novel bioelectric medicine company. It offers CellFX System, a novel Nanosecond Pulsed-Field Ablation delivery platform to treat benign lesions of the skin; CellFX nsPFA Percutaneous Electrode system for soft tissue ablation in surgical setting; CellFX nsPFA Cardiac Clamp designed for use in surgical treatment of atrial fibrillation (AF); CellFX nsPFA 360° Cardiac Catheter designed to provide a circumferential, or circular, ablation in a single treatment cycle; and The CellFX Consol, a tunable, software-enabled, and console-based platform designed to accommodate the clinical workflow preferred by physicians. The company was formerly known as Electroblate, Inc. and changed its name to Pulse Biosciences, Inc. in December 2015.
Pulse Biosciences, Inc. Fundamentals Summary
| PLSE fundamental statistics | |
|---|---|
| Market cap | US$1.03b |
| Earnings (TTM) | -US$60.24m |
| Revenue (TTM) | n/a |
Is PLSE overvalued?
See Fair Value and valuation analysisEarnings & Revenue
| PLSE income statement (TTM) | |
|---|---|
| Revenue | US$0 |
| Cost of Revenue | US$0 |
| Gross Profit | US$0 |
| Other Expenses | US$60.24m |
| Earnings | -US$60.24m |
Last Reported Earnings
Mar 31, 2025
Next Earnings Date
n/a
| Earnings per share (EPS) | -0.90 |
| Gross Margin | 0.00% |
| Net Profit Margin | 0.00% |
| Debt/Equity Ratio | 0% |
How did PLSE perform over the long term?
See historical performance and comparisonCompany Analysis and Financial Data Status
| Data | Last Updated (UTC time) |
|---|---|
| Company Analysis | 2025/06/20 13:31 |
| End of Day Share Price | 2025/06/20 00:00 |
| Earnings | 2025/03/31 |
| Annual Earnings | 2024/12/31 |
Data Sources
The data used in our company analysis is from S&P Global Market Intelligence LLC. The following data is used in our analysis model to generate this report. Data is normalised which can introduce a delay from the source being available.
| Package | Data | Timeframe | Example US Source * |
|---|---|---|---|
| Company Financials | 10 years |
| |
| Analyst Consensus Estimates | +3 years |
|
|
| Market Prices | 30 years |
| |
| Ownership | 10 years |
| |
| Management | 10 years |
| |
| Key Developments | 10 years |
|
* Example for US securities, for non-US equivalent regulatory forms and sources are used.
Unless specified all financial data is based on a yearly period but updated quarterly. This is known as Trailing Twelve Month (TTM) or Last Twelve Month (LTM) Data. Learn more.
Analysis Model and Snowflake
Details of the analysis model used to generate this report is available on our Github page, we also have guides on how to use our reports and tutorials on Youtube.
Learn about the world class team who designed and built the Simply Wall St analysis model.
Industry and Sector Metrics
Our industry and section metrics are calculated every 6 hours by Simply Wall St, details of our process are available on Github.
Analyst Sources
Pulse Biosciences, Inc. is covered by 3 analysts. 0 of those analysts submitted the estimates of revenue or earnings used as inputs to our report. Analysts submissions are updated throughout the day.
| Analyst | Institution |
|---|---|
| Swayampakula Ramakanth | H.C. Wainwright & Co. |
| Anthony Vendetti | Maxim Group |
| Christopher Cooley | Stephens, Inc. |